Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging.

Lala M, Burckart GJ, Takao CM, Pravica V, Momper JD, Gobburu JV.

J Pediatr Pharmacol Ther. 2013 Jul;18(3):209-19. doi: 10.5863/1551-6776-18.3.209.

2.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
3.

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients.

Park SM, Lee JK, Chun SI, Lee HI, Kwon SU, Kang DW, Kim JS.

J Stroke. 2013 May;15(2):115-21. doi: 10.5853/jos.2013.15.2.115. Epub 2013 May 31.

4.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F.

Blood. 2005 Oct 1;106(7):2329-33. Epub 2005 Jun 9.

5.
6.

The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.

Tatarūnas V, Lesauskaitė V, Veikutienė A, Jakuška P, Benetis R.

Medicina (Kaunas). 2011;47(1):25-30.

7.

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.

Haug KB, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, Kierulf P, Seljeflot I, Arnesen H, Brørs O.

Thromb J. 2008 Jun 17;6:7. doi: 10.1186/1477-9560-6-7.

8.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
9.

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D.

Blood. 2009 Apr 23;113(17):3925-30. doi: 10.1182/blood-2008-09-176859. Epub 2008 Dec 12.

10.

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Molden E, Okkenhaug C, Ekker Solberg E.

Eur J Clin Pharmacol. 2010 May;66(5):525-30. doi: 10.1007/s00228-010-0813-6. Epub 2010 Mar 31.

PMID:
20354686
11.

Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.

Smires FZ, Moreau C, Habbal R, Siguret V, Fadili S, Golmard JL, Assaidi A, Beaune P, Loriot MA, Nadifi S.

J Clin Pharm Ther. 2012 Oct;37(5):594-8. doi: 10.1111/j.1365-2710.2012.01340.x. Epub 2012 Apr 8.

PMID:
22486182
12.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
13.

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

Biss TT, Avery PJ, Brandão LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F.

Blood. 2012 Jan 19;119(3):868-73. doi: 10.1182/blood-2011-08-372722. Epub 2011 Oct 18.

14.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3.

PMID:
19077919
15.

Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.

El Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, Mohamed AM.

Int J Lab Hematol. 2012 Oct;34(5):517-24. doi: 10.1111/j.1751-553X.2012.01426.x. Epub 2012 Apr 26.

PMID:
22533669
16.

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.

Gao L, He L, Luo J, Xu B, Yang J, Zhang YX, Yang T, Li K, Tian JW, Wang HJ, Zhao YS, Lu CY, Zhang WZ, Yin T.

Chin Med J (Engl). 2011 Sep;124(17):2767-70.

17.

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Yin T, Miyata T.

Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11. Review.

PMID:
17161452
18.

Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.

Kwon A, Jo SH, Im HJ, Jo YA, Park JY, Kang HJ, Kim HS, Cho HC, Lee YK.

J Thromb Thrombolysis. 2011 Nov;32(4):467-73. doi: 10.1007/s11239-011-0616-3.

PMID:
21713378
19.

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.

Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, Tai SS.

BMC Med Genet. 2011 Jun 6;12:80. doi: 10.1186/1471-2350-12-80.

20.

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

Linder MW, Bon Homme M, Reynolds KK, Gage BF, Eby C, Silvestrov N, Valdes R Jr.

Clin Chem. 2009 Oct;55(10):1861-8. doi: 10.1373/clinchem.2009.125898. Epub 2009 Aug 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk